Previous Award winners include Napoleone Ferrara, M.D., Genentech Fellow; Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases (NIAID); Erik De Clercq, M.D., Ph.D., chairman, Department of Microbiology and Immunology, Medical School at the Catholic University of Leuven; Axel Ullrich, Ph.D., director, Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany; Professor Marc Feldmann, FMedSci, FAA, FRS, and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS, of the Kennedy Institute of Rheumatology, Imperial College London; and Craig Mello, Ph.D., Nobel Laureate, of the Howard Hughes Medical Institute and University of Massachusetts Medical School.
Beyond the passion and creativity Dr.
demonstrated in the laboratory, he also inspired and mentored many young scientific leaders who went on to great achievements in addressing medical need.
"As in past years, we look forward to selecting a 2013 Dr.
Award winner(s) from among the nominations of worthy individuals in research institutions and companies around the world, who has significantly improved human health through dedication to the advancement of science and medicine," said
Howard Hughes Medical Institute Investigator
and Professor, Program in Molecular Medicine,
University of Massachusetts Medical School
and 2013 chair of the Dr.
Award Selection Committee.
The 2013 Dr.
Award winner will be announced in spring 2013.
About The Dr. Paul Janssen Award for Biomedical Research
Established by Johnson & Johnson, The Dr.
Award salutes the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Dr.
Award is named for Dr.
, who founded Janssen Pharmaceutica, N.V., in 1953. Known to his colleagues as "Dr. Paul," Janssen was one of the 20th century's most gifted and passionate researchers, a physician-scientist who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit
for more information.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson (NYSE: JNJ). We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 129,000 employees at more than 250 Johnson & Johnson companies work with partners in healthcare to touch the lives of over a billion people every day, throughout the world.
Johnson & Johnson Services, Inc.908-218-6460 or
Janssen Global Services, LLC908-927-6171 or
Janssen Global Services, LLC+32 14 60 57 24 or
SOURCE Johnson & Johnson